A Clear Horizon in Plaque Psoriasis: An Update on Investigational Oral Therapies
Автор: ReachMD
Загружено: 2025-12-01
Просмотров: 15
Faculty: Linda Stein Gold, MD
Faculty: April W. Armstrong, MD, MPH
Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of plaque psoriasis. Investigation into novel oral small-molecule therapies is ongoing, such as next-generation TYK2 inhibitors and the first-in-class investigational targeted oral peptide icotrokinra, which selectively targets IL-23 receptor signaling. These therapies have demonstrated dramatically improved clinical responses versus comparators and may significantly impact the current treatment paradigm for plaque psoriasis.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
